OSF Saint Francis Radiation Oncology at Peoria Cancer Center

Summary

OSF Saint Francis Radiation Oncology at Peoria Cancer Center is a medical facility located in Peoria, Illinois. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer and other specialties. OSF Saint Francis Radiation Oncology at Peoria Cancer Center is involved with conducting 167 clinical trials across 317 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.

Top PIs

Clinical Trials running at OSF Saint Francis Radiation Oncology at Peoria Cancer Center

Lung Cancer

Testicular cancer

Bladder Cancer

Oropharyngeal Carcinoma

Cancer

Breast Cancer

Prostate Cancer

Gastric cancer

Ovarian Carcinoma

Ovarian Tumors

High-Dose Radiation + Chemotherapy and Immunotherapy

for Non-Small Cell Lung Cancer

This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.

Recruiting

2 awards

Phase 3

14 criteria

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria